Edition:
United States

Oramed Pharmaceuticals Inc (ORMP.OQ)

ORMP.OQ on NASDAQ Stock Exchange Capital Market

7.38USD
18 Apr 2018
Change (% chg)

-- (--)
Prev Close
$7.38
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,482
52-wk High
$11.34
52-wk Low
$6.19

Chart for

About

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible... (more)

Overall

Beta: 0.49
Market Cap(Mil.): $106.06
Shares Outstanding(Mil.): 14.37
Dividend: --
Yield (%): --

Financials

  ORMP.OQ Industry Sector
P/E (TTM): -- 199.23 33.71
EPS (TTM): -0.73 -- --
ROI: -28.70 -0.66 13.09
ROE: -48.36 -2.84 14.92

BRIEF-Oramed Pharmaceuticals' Unit Enters Clinical Research Organization Services Agreement With Integrium

* SAYS ON FEB 14, A UNIT ENTERED CLINICAL RESEARCH ORGANIZATION SERVICES AGREEMENT WITH INTEGRIUM EFFECTIVE AS OF NOV 1, 2017‍​

Feb 20 2018

BRIEF-Oramed receives approval for clinical study to treat NASH

* Oramed receives regulatory approval to conduct clinical study for treatment of NASH with its oral insulin capsule

Nov 14 2017

Earnings vs. Estimates